PREDICTORS OF OUTCOME AND SURVIVAL IN PROSTATE CANCER – DATA FROM TERTIARY CARE UROLOGY INSTITUTE IN PAKISTAN

Código QR

PREDICTORS OF OUTCOME AND SURVIVAL IN PROSTATE CANCER – DATA FROM TERTIARY CARE UROLOGY INSTITUTE IN PAKISTAN

Guardado en:

Detalles Bibliográficos
Autor principal:	Syed Najeeb Niamatullah
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/dfff9300a57d46b7b8cf236e75b0da0b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

EVALUATION OF APPROPRIATE USE OF PEDIATRIC FRESH FROZEN PLASMA IN A TERTIARY CARE HOSPITAL
por: Dilek GURLEK GOKCEBAY, et al.
Publicado: (2021)

Heritable Thrombophilia in Venous Thromboembolism in Northern Pakistan: A Cross-Sectional Study
por: Maria Khan, et al.
Publicado: (2021)

THE OUTCOME OF FATHERHOOD IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS, A SINGLE INSTITUTION EXPERIENCE
por: Elrazi Ali, et al.
Publicado: (2021)

CHARACTERISTICS AND OUTCOME OF T(8;21)-POSITIVE CHILDHOOD ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION'S EXPERIENCE
por: Volkan KÖSE, et al.
Publicado: (2021)

THE IMPACT OF HEMATOLOGICAL PARAMETERS ON SURVIVAL FOR PATIENTS WITH COVID-19
por: Fatma YILMAZ, et al.
Publicado: (2021)

HAEMOPHILIA AND NURSING CARE
por: Marcela Ganzella
Publicado: (2021)

THE EFFECT OF COMORBIDITY AND BODY MASS INDEX ON SURVIVAL IN PATIENTS WITH MARGINAL ZONE LYMPHOMA
por: Esra TURAN ERKEK, et al.
Publicado: (2021)

THE EFFECT OF BISPHOSPHONATE USE ON TREATMENT RESPONSE AND OVERALL SURVIVAL IN MULTIPLE MYELOMA PATIENTS
por: Ayşe Uysal, et al.
Publicado: (2021)

AN UNUSUAL SURVIVING HISTORY: MULTISYSTEM INVOLVEMENT UNTIL ADULT LIFE WITH NIEMANN PICK TYPE B
por: Özden ÖZLÜK, et al.
Publicado: (2021)

CLINICAL CHARACTERISTICS, AND SURVIVAL RATE OF ELDERLY PATIENTS WITH NON-HODGKIN'S LYMPHOMAS WITH PRIMARY INVOLVEMENT OF PERIPHERAL LYMPH NODES
por: Tomacinschii Victor, et al.
Publicado: (2021)

THE IMPACT OF TYROSINE KINASE INHIBITORS ON FATHERHOOD IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA, A SINGLE INSTITUTION EXPERIENCE
por: Mohammad Abu-Tineh, et al.
Publicado: (2021)

LATE EFFECTS OF CHILDHOOD CANCER: THE FOUNDATION FOR RISK-STRATIFIED PEDIATRIC CANCER CARE LONG TERM
por: Melissa M. Hudson
Publicado: (2021)

MANAGEMENT AND OUTCOMES OF NEUTROPENIA IN PREVIOUSLY HEALTHY CHILDREN
por: Hatice Mine Cakmak, et al.
Publicado: (2021)

OUTCOME OF SPLENECTOMY IN THE TREATMENT OF ITP – ONE CENTER EXPERIENCE
por: Weronika Lebowa, et al.
Publicado: (2021)

ACUTE ABDOMEN AND ITS OUTCOMES IN CHILDREN WITH ACUTE LEUKEMIA
por: Huseyin Avnı Solgun, et al.
Publicado: (2021)

ACQUIRED FACTOR XIII DEFICIENCY WITH RUNX1 MUTATION, A REPORT OF TWO CASES TREATED WITH FACTOR XIII CONCENTRATE
por: Alfadil Haroon, et al.
Publicado: (2021)

THE OUTCOME OF IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDHOOD AND THE RISK FACTORS FOR CHRONICITY
por: Barış YILMAZ, et al.
Publicado: (2021)

A method to determine if more than surrogate outcomes were improved: The EMR glitch experiment
por: Jennifer Gill, et al.
Publicado: (2020)

AVASCULAR NECROSIS IN CHRONIC MYELOID LEUKEMIA: A REVIEW OF PATHOPHYSIOLOGY, PATIENTS’ CHARACTERISTICS, AND CLINICAL OUTCOMES
por: Abdulrahman Al-Mashdali, et al.
Publicado: (2021)

COMPARABLE OUTCOMES OF ALLOGENEIC PERIPHERAL BLOOD VERSUS BONE MARROW HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN
por: AYÇA KOCA YOZGAT, et al.
Publicado: (2021)

OUTCOMES OF ALLOGENEIC SC TRANSPLANT IN HEMATOLOGICAL MALIGNANCY PATIENTS USING BUSULFAN 3 (9.6 MG/KG) BASED CONDITIONING REGIMEN
por: Majed Altareb, et al.
Publicado: (2021)

EPIDEMIOLOGY, TREATMENT PATTERNS, AND CLINICAL OUTCOMES AMONG PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) IN THE UNITED STATES: AN ELECTRONIC HEALTH RECORDS ANALYSIS
por: Ayoade Adeyemi, et al.
Publicado: (2021)

The absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use
por: Kaufman GP, et al.
Publicado: (2014)

Trends in the treatment of cutaneous T-cell lymphoma &ndash; critical evaluation and perspectives on vorinostat
por: Zhang CL, et al.
Publicado: (2012)

MicroRNA dysregulation in B-cell non-Hodgkin lymphoma
por: Lim EL, et al.
Publicado: (2013)

Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations
por: Bodiford A, et al.
Publicado: (2015)

The expanding role of bendamustine in chronic lymphocytic leukemia
por: Nair KS, et al.
Publicado: (2015)

Bortezomib in autoimmune hemolytic anemia and beyond
por: Raffaella Pasquale, et al.
Publicado: (2021)

Life-Threatening Retroperitoneal Hematoma in a Patient with COVID-19
por: Monarch Shah, et al.
Publicado: (2021)

All bleeding matters … but the details may not
por: Sarah H. O’Brien
Publicado: (2020)

The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma
por: Eko A. Pangarsa, et al.
Publicado: (2021)

PP Transcon 2020 Abstracts Compilation
Publicado: (2021)

Positive/external control of rapid diagnostic tests: A step forward in malaria screening
por: Rasika D Setia, et al.
Publicado: (2021)

A rare case of mistaken identity - Historical blood group saved the situation
por: Anand Deshpande, et al.
Publicado: (2021)

Oration - Dr Sanmukh Joshi
Publicado: (2021)

OP Transcon 2020 Abstracts Compilation
Publicado: (2021)

TRANSCON 2020 45th Annual Conference ISBTI 27th & 28th Feb 2021
Publicado: (2021)

Clinical relevance of hepatitis B core total antibody in the detection of occult hepatitis B infection in patients with liver disease and blood donors
por: Vijeta Bajpai, et al.
Publicado: (2021)

Long-term safety and efficacy of dasatinib in the treatment of chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib
por: Shoumariyeh K, et al.
Publicado: (2014)

MYC as therapeutic target in leukemia and lymphoma
por: Cortiguera MG, et al.
Publicado: (2015)